Literature DB >> 10486457

Recurrent cervical carcinoma after primary radical surgery.

C J Wang1, C H Lai, H J Huang, J H Hong, H H Chou, K G Huang, J D Lin.   

Abstract

OBJECTIVE: This study was undertaken to investigate prognostic factors in patients with recurrent cervical carcinoma who had undergone a primary radical hysterectomy and pelvic lymphadenectomy. STUDY
DESIGN: A retrospective analysis of 177 patients with recurrent cervical carcinoma after radical hysterectomy and pelvic lymphadenectomy for stage IB to II disease at a single institution was performed to evaluate clinicopathologic parameters, time to recurrence, pattern of failure, use of salvage therapy, and survival after recurrence.
RESULTS: The 5-year survival rate from diagnosis of recurrence in this series was 10.1%. Survival after recurrence was significantly decreased in patients with pelvic lymph node metastasis at primary surgery and adenocarcinoma-adenosquamous carcinoma histologic type. Patients with extravaginal recurrences receiving chemoradiation for recurrent cervical carcinoma had significantly better outcomes than those receiving radiation alone. Six patients who had a distant relapse at a sole site had prolonged survival after salvage therapy, which was accomplished by chemoradiation, surgery plus radiotherapy, or surgery alone.
CONCLUSIONS: Our results demonstrate the benefit of adding chemotherapy to radiotherapy in the treatment of recurrent cervical carcinoma. Salvage multimodality treatment should be offered to selected patients who have isolated relapse at a single distant site.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10486457     DOI: 10.1016/s0002-9378(99)70486-2

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  15 in total

1.  The Correlation Between the Serum Squamous Carcinoma Antigen and the Prognosis of Recurrent Cervical Squamous Carcinoma.

Authors:  Yan Wang; Tong Cui; Lili Du; Xiaoqin Xu; Baoguo Tian; Ting Sun; Cunzhi Han; Xianwen Zhao; Jiexian Jing
Journal:  J Clin Lab Anal       Date:  2016-07-20       Impact factor: 2.352

2.  Nuclear localizaiton of β-catenin is associated with poor survival and chemo-/radioresistance in human cervical squamous cell cancer.

Authors:  Yanna Zhang; Bangzhong Liu; Qingyu Zhao; Teng Hou; Xin Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 3.  Long-term experience with (laterally) extended endopelvic resection (LEER) in relapsed pelvic malignancies.

Authors:  Michael Höckel
Journal:  Curr Oncol Rep       Date:  2015-03       Impact factor: 5.075

4.  Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.

Authors:  Israel Zighelboim; Jason D Wright; Feng Gao; Ashley S Case; L Stewart Massad; David G Mutch; Matthew A Powell; Premal H Thaker; Eric L Eisenhauer; David E Cohn; Fidel A Valea; Angeles Alvarez Secord; Lynne T Lippmann; Farrokh Dehdashti; Janet S Rader
Journal:  Gynecol Oncol       Date:  2013-04-13       Impact factor: 5.482

5.  Early invasive cervical cancer: MRI and CT predictors of lymphatic metastases in the ACRIN 6651/GOG 183 intergroup study.

Authors:  Donald G Mitchell; Bradley Snyder; Fergus Coakley; Caroline Reinhold; Gillian Thomas; Marco A Amendola; Lawrence H Schwartz; Paula Woodward; Harpreet Pannu; Mostafa Atri; Hedvig Hricak
Journal:  Gynecol Oncol       Date:  2008-11-20       Impact factor: 5.482

6.  3D radiation therapy or intensity-modulated radiotherapy for recurrent and metastatic cervical cancer: the Shanghai Cancer Hospital experience.

Authors:  Su-Ping Liu; Xiao Huang; Gui-Hao Ke; Xiao-Wei Huang
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

7.  The prognosis of women with stage IB1-IIB node-positive cervical carcinoma after radical surgery.

Authors:  Xi Cheng; Shumo Cai; Ziting Li; Meiqin Tang; Muquan Xue; Rongyu Zang
Journal:  World J Surg Oncol       Date:  2004-12-18       Impact factor: 2.754

8.  Practice guidelines for management of cervical cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement.

Authors:  Myong Cheol Lim; Maria Lee; Seung Hyuk Shim; Eun Ji Nam; Jung Yun Lee; Hyun Jung Kim; Yoo Young Lee; Kwang Beom Lee; Jeong Yeol Park; Yun Hwan Kim; Kyung Do Ki; Yong Jung Song; Hyun Hoon Chung; Sunghoon Kim; Jeong Won Lee; Jae Weon Kim; Duk Soo Bae; Jong Min Lee
Journal:  J Gynecol Oncol       Date:  2017-03-15       Impact factor: 4.401

Review 9.  Wnt signaling in cervical cancer?

Authors:  Min Yang; Min Wang; Xianping Li; Yixin Xie; Xiaomeng Xia; Jingjing Tian; Kan Zhang; Aiguo Tang
Journal:  J Cancer       Date:  2018-03-20       Impact factor: 4.207

10.  FEZF1 is an Independent Predictive Factor for Recurrence and Promotes Cell Proliferation and Migration in Cervical Cancer.

Authors:  Yang Lan; Xuewei Xiao; Yu Luo; Zhengchi He; Xu Song
Journal:  J Cancer       Date:  2018-10-10       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.